Leucine alters hepatic glucose/lipid homeostasis via the myostatin-AMP-activated protein kinase Pathway - Potential implications for nonalcoholic fatty liver disease

Clinical Epigenetics

Volumn 6, Issue 1, 2014, Pages

  Zarfeshani, Aida ^a   Ngo, Sherry ^a   Sheppard, Allan M ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

AMP activated protein kinase; Fatty liver; Leucine; miRNAs; Myostatin

Indexed keywords

GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LEUCINE; LIPID; MICRORNA; MYOSTATIN; TRIACYLGLYCEROL;

ARTICLE; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID HOMEOSTASIS; LIPID STORAGE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84986269498     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1186/1868-7083-6-27     Document Type: Article

References (49)

1. Layman DK: The role of leucine in weight loss diets and glucose homeostasis. J Nutr 2003, 133: 261S-267S.
2. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Newgard: A branched-chain amino acidrelated metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009, 9: 311-326.
3. Corkey BE: Banting lecture 2011 hyperinsulinemia: cause or consequence?. Diabetes 2012, 61: 4-13.
4. Lu J, Xie G, Jia W, Jia W: Insulin resistance and the metabolism of branched-chain amino acids. Front Med 2013, 7: 53-59.
5. Layman DK, Walker DA: Potential importance of leucine in treatment of obesity and the metabolic syndrome. J Nutr 2006, 136: 319S-323S.
6. Zhang Y, Guo K, LeBlanc RE, Loh D, Schwartz GJ, Yu Y-H: Increasing dietary leucine intake reduces diet-induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms. Diabetes 2007, 56: 1647-1654.
7. Nishitani S, Matsumura T, Fujitani S, Sonaka I, Miura Y, Yagasaki K: Leucine promotes glucose uptake in skeletal muscles of rats. Biochem Biophys Res Commun 2002, 299: 693-696.
8. Oddy WH, Herbison CE, Jacoby P, Ambrosini GL, O’Sullivan TA, Ayonrinde OT, Olynyk JK, Black LJ, Beilin LJ, Mori TA: The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. Am J Gastroenterol 2013, 108: 778-785.
9. Erickson SK: Nonalcoholic fatty liver disease. J Lipid Res 2009, 50: S412-S416.
10. Nordlie RC, Foster JD, Lange AJ: Regulation of glucose production by the liver. Annu Rev Nutr 1999, 19: 379-406.
11. Aiston S, Trinh KY, Lange AJ, Newgard CB, Agius L: Glucose-6-phosphatase overexpression lowers glucose 6-phosphate and inhibits glycogen synthesis and glycolysis in hepatocytes without affecting glucokinase translocation evidence against feedback inhibition of glucokinase. J Biol Chem 1999, 274: 24559-24566.
12. Im S-S, Kim J-W, Kim T-H, Song X-L, Kim S-Y, Kim HI, Ahn Y-H: Identification and characterization of peroxisome proliferator response element in the mouse GLUT2 promoter. Exp Mol Med 2005, 37: 101-110.
13. Bae J-S, Kim T-H, Kim M-Y, Park J-M, Ahn Y-H: Transcriptional regulation of glucose sensors in pancreatic β-Cells and liver: an update. Sensors 2010, 10: 5031-5053.
14. Xu H, Wilcox D, Nguyen P, Voorbach M, Suhar T, Morgan SJ, An WF, Ge L, Green J, Wu Z: Hepatic knockdown of mitochondrial GPAT1 in ob/ob mice improves metabolic profile. Biochem Biophys Res Commun 2006, 349: 439-448.
15. Abdel-Magid AF: Treatment of obesity and related disorders with acetyl-CoA carboxylase Inhibitors. ACS Med Chem Lett 2012, 4: 16-17.
16. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, Kitamura Y, Altomonte J, Dong H, Accili: Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1α interaction. Nature 2003, 423: 550-555.
17. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong HH: FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 2008, 118: 2347-2364.
18. Laplante M, Sabatini DM: mTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis. Proc Natl Acad Sci 2010, 107: 3281-3282.
19. Tzatsos A, Kandror KV: Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 2006, 26: 63-76.
20. Fdr T, Gagnon A, Veilleux A, Sorisky A, Marette A: Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3 T3-L1 and human adipocytes. Endocrinology 2005, 146: 1328-1337.
21. Kovacic S, Soltys C-LM, Barr AJ, Shiojima I, Walsh K, Dyck JRB: Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem 2003, 278: 39422-39427.
22. Hittel DS, Berggren JR, Shearer J, Boyle K, Houmard JA: Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes 2009, 58: 30-38.
23. Allen DL, Cleary AS, Speaker KJ, Lindsay SF, Uyenishi J, Reed JM, Madden MC, Mehan RS: Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am J Physiol Endocrinol Metab 2008, 294: E918-E927.
24. Adams SH: Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr 2011, 2: 445-456.
25. Fisher JS, Gao J, Han D-H, Holloszy JO, Nolte LA: Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol Endocrinol Metabol 2002, 282: E18-E23.
26. Iglesias MA, Ye J-M, Frangioudakis G, Saha AK, Tomas E, Ruderman NB, Cooney GJ, Kraegen EW: AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 2002, 51: 2886-2894.
27. Chen Y, Ye J, Cao L, Zhang Y, Xia W, Zhu D: Myostatin regulates glucose metabolism via the AMP-activated protein kinase pathway in skeletal muscle cells. Int J Biochem Cell Biol 2010, 42: 2072-2081.
28. Zhao B, Wall RJ, Yang J: Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance. Biochem Biophys Res Commun 2005, 337: 248-255.
29. Wilkes JJ, Lloyd DJ, Gekakis N: Loss-of-function mutation in myostatin reduces tumor necrosis factor α production and protects liver against obesity-induced insulin resistance. Diabetes 2009, 58: 1133-1143.
30. Milan G, Dalla Nora E, Pilon C, Pagano C, Granzotto M, Manco M, Mingrone G, Vettor R: Changes in muscle myostatin expression in obese subjects after weight loss. J Clin Endocrinol Metabol 2004, 89: 2724-2727.
31. Park J-J, Berggren JR, Hulver MW, Houmard JA, Hoffman EP: GRB14, GPD1, and GDF8 as potential network collaborators in weight loss-induced improvements in insulin action in human skeletal muscle. Physiol Genomics 2006, 27: 114-121.
32. Allen DL, Hittel DS, McPherron AC: Expression and function of myostatin in obesity, diabetes, and exercise adaptation. Med Sci Sports Exerc 2011, 43: 1828.
33. Sanchez AMJ, Candau RB, Csibi A, Pagano AF, Raibon A, Bernardi H: The role of AMP-activated protein kinase in the coordination of skeletal muscle turnover and energy homeostasis. Am J Physiol Cell Physiol 2012, 303: C475-C485.
34. Inoue M, Ohtake T, Motomura W, Takahashi N, Hosoki Y, Miyoshi S, Suzuki Y, Saito H, Kohgo Y, Okumura T: Increased expression of PPARγ in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun 2005, 336: 215-222.
35. Zhang C, McFarlane C, Lokireddy S, Bonala S, Ge X, Masuda S, Gluckman PD, Sharma M, Kambadur R: Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia 2011, 54: 1491-1501.
36. McPherron AC, Lee S-J: Suppression of body fat accumulation in myostatin-deficient mice. J Clin Investig 2002, 109: 595-601.
37. Burgess K, Xu T, Brown R, Han B, Welle S: Effect of myostatin depletion on weight gain, hyperglycemia, and hepatic steatosis during five months of high-fat feeding in mice. PLoS One 2011, 6: e17090.
38. Goldberg IJ, Ginsberg HN: Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease. Gastroenterology 2006, 130: 1343-1346.
39. Attie AD, Scherer PE: Adipocyte metabolism and obesity. J Lipid Res 2009, 50: S395-S399.
40. Adiels M, Taskinen M-R, Borén J: Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 2008, 8: 60-64.
41. Tang X, Muniappan L, Tang G, Özcan S: Identification of glucose-regulated miRNAs from pancreatic β cells reveals a role for miR-30d in insulin transcription. RNA 2009, 15: 287-293.
42. Plaisance V, Abderrahmani A, Perret-Menoud V, Jacquemin P, Lemaigre F, Regazzi R: MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem 2006, 281: 26932-26942.
43. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, MacDonald PE, Pfeffer S, Tuschl T, Rajewsky N, Rorsman P: A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004, 432: 226-230.
44. Baroukh N, Ravier MA, Loder MK, Hill EV, Bounacer A, Scharfmann R, Rutter GA, Van Obberghen E: MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic β-cell lines. J Biol Chem 2007, 282: 19575-19588.
45. Heneghan HM, Miller N, Kerin MJ: Role of microRNAs in obesity and the metabolic syndrome. Obes Rev 2010, 11: 354-361.
46. Fernandez-Valverde SL, Taft RJ, Mattick JS: MicroRNAs in β-cell biology, insulin resistance, diabetes and its complications. Diabetes 2011, 60: 1825-1831.
47. Wang Q, Li YC, Wang J, Kong J, Qi Y, Quigg RJ, Li X: miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumorsuppressor Rb2/p130. Proc Natl Acad Sci 2008, 105: 2889-2894.
48. Zhu L, Chen L, Shi C-M, Xu G-F, Xu L-L, Zhu L-L, Guo X-R, Ni Y, Cui Y, Ji C: MiR-335, an adipogenesis-related MicroRNA, is involved in adipose tissue inflammation. Cell Biochem Biophys 2014, 68: 283-290.
49. Ha DT, Trung TN, Hien TT, Dao TT, Yim N, Ngoc TM, Oh WK, Bae K: Selected compounds derived from Moutan Cortex stimulated glucose uptake and glycogen synthesis via AMPK activation in human HepG2 cells. J Ethnopharmacol 2010, 131: 417-424.